Xbrane Biopharma AB Asset Resilience Ratio
Xbrane Biopharma AB asset resilience ratio. Xbrane Biopharma AB (XBRANE) has an Asset Resilience Ratio of 12.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xbrane Biopharma AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xbrane Biopharma AB (2016–2016)
Asset resilience ratio of Xbrane Biopharma AB from 2016 to 2016. This chart shows how Xbrane Biopharma AB's Asset Resilience Ratio has changed over time. Read Xbrane Biopharma AB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xbrane Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Xbrane Biopharma AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr86.59 Million | 12.89% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr86.59 Million | 12.89% |
Asset Resilience Insights
- Moderate Liquidity: Xbrane Biopharma AB has 12.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xbrane Biopharma AB Industry Peers by Asset Resilience Ratio
Compare Xbrane Biopharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Xbrane Biopharma AB Asset Resilience Ratio by Year (2016–2016)
Xbrane Biopharma AB asset resilience ratio by year from 2016 to 2016. The table below shows the annual Asset Resilience Ratio data for Xbrane Biopharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 26.53% | Skr31.34 Million ≈ $3.37 Million |
Skr118.11 Million ≈ $12.71 Million |
-- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more